Seven More Products are Approved by US FDA

Two oral contraceptive products, two immediate-release products and three extended-release products, all NOVAST-develope....

Best Business Partner of the Year 2019 Awarded by Ingenus

In November, NOVAST receives the award of “Best Business Partner of the Year 2019” from INGENUS in recogniti....

Best Supplier of the Year 2018 awarded by NorthStar Healthcare UC (Mckesson)

This award ceremony is held on August 28, 2019.NOVAST management team and employee representatives are in attendance. On....

Another Three Products are Approved by US FDA

One oral contraceptive product (Malmorede™) and two extended-release products (Metoprolol Succinate ER Tablets and....

Sixth Successful US FDA CGMP Inspection with ZERO 483 Observations

FDA investigator conducts the sixth CGMP inspection from July 9th to July 13th, 2018 and NOVAST passes inspection with Z....

Metoprolol Succinate ER Tablets is Launched into the US Market

NOVAST-developed Metoprolol Succinate ER Tablets, USP receives approval fromUS FDA on February 7th, 2018 after more than....

Another Two Products are Approved by US FDA

NOVAST-developed Indomethacin ER Capsules and Quetiapine Fumarate ER Tablets are approved by the US FDA in 2017.

The Fifth Successful US FDA cGMP Inspection with ZERO 483 Observations

The Fifth Successful US FDA CGMP Inspection with ZERO 483 Observations occurred from July 10 to July 14, 2017.